Hypertrophic Cardiomyopathy Association to Sponsor Bighearted 5K to Support Patients & Families
Bighearted 5K 2026, to benefit the HCMA, seeks virtual & in-person runners & walkers to keep families whole, one step
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Bighearted 5K 2026, to benefit the HCMA, seeks virtual & in-person runners & walkers to keep families whole, one step at a time.
DENVILLE, NJ, UNITED STATES, September 9, 2026 /EINPresswire.com/ — September 3, 2026. The Hypertrophic Cardiomyopathy Association (HCMA) is sponsoring the 2nd Annual Bighearted 5K on Sunday, October 11, at 66 Ford Road in Denville, NJ. More than a run, it is an opportunity to contribute to a great cause and have fun while doing it.
The event starts at 9 AM, with the race beginning at 10 AM. The will feature music, food trucks, a bounce house for the littles, and a memory walk in honor of those lost to hypertrophic cardiomyopathy (HCM), and awards for top finishers in various categories. Participants can register in 1 of 4 categories:
5K Run/Walk
5K Run/Walk – Untimed
Virtual 5K-Untimed
1 Mile Fun Run – Untimed
We are offering fundraising incentives!
Last year, more than 200 runners, walkers, families, and friends came together for the HCMA’s inaugural Bighearted 5K. The event raised nearly $30,000 to support HCMA’s mission to advocate for, educate, and empower those affected by HCM and all thick heart muscle disorders.
We offer sponsorship opportunities for local businesses, including PA announcements throughout the event, promotional opportunities, complimentary race entries, and promotional items in the race swag bag.
HCMA would like to thank our sponsors who make this day possible. We gratefully acknowledge our Diamond Sponsors (Bristol Myers Squibb, Cytokinetics, and Edgewise Therapeutics), our Sapphire Sponsor (BridgeBio), and our Emerald Sponsors (Alnylam, Braveheart Bio, Lexicon Pharmaceuticals, Rocket Pharmaceuticals, and Tenaya Therapeutics).
About Hypertrophic Cardiomyopathy (HCM)
HCM is a genetic heart condition that causes the heart muscle to harden. It impacts between 1:250 and 1:500 people globally. Approximately 85% of those who have HCM remain undiagnosed.
About the Hypertrophic Cardiomyopathy Association (HCMA)
The HCMA was founded in 1996 to support, advocate for, and educate patients, families, the medical community, and the public about hypertrophic cardiomyopathy and all thick heart muscle disorders, while supporting research and the development of treatments and diagnostics. The HCMA is a 501(c)(3) headquartered in Denville, NJ.
Claudine D’Angelo-Dotzman
Hypertrophic Cardiomyopathy Association
+1 973-983-7429
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
